Search

Displaying results 1181 - 1190 of 4591 in total
  1. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    Nevertheless, xylose by itself may not necessarily serve many purposes immediately - but its metabolism results in a variety of substrates that can serve important nutritional and biological purposes. … Reduction of xylose by catalytic hydrogenation produces the common food additive sweetener substitute xylitol [DB11195].

  2. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific

  3. Drug

    Glucarpidase

    go.drugbank.com/drugs/DB08898
    ApprovedInvestigational

    [L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE. … Glucarpidase is a recombinant carboxypeptidase G2 produced by genetically modified _Escherichia coli_ bacteria. It is a 390-amino acid homodimer protein.

  4. Drug

    Simethicone

    go.drugbank.com/drugs/DB09512
    ApprovedInvestigational

    [A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308]

    Mixtures: DYNA-U TABLET, DYNA U SUSPENSION
  5. Drug

    Paritaprevir

    go.drugbank.com/drugs/DB09297
    ApprovedInvestigational

    Lack of significant side effects and short duration of therapy is a considerable advantage over older interferon-based regimens, which were limited by infusion site reactions, reduced blood count, and … By inhibiting viral protease NS3/4A, paritaprevir therefore prevents viral replication and function.

  6. Drug

    Pralidoxime

    go.drugbank.com/drugs/DB00733
    ApprovedInvestigationalVet approved

    If given within 24 hours,after organophosphate exposure, pralidoxime reactivates the enzyme cholinesterase by cleaving the phosphate-ester bond formed between the organophosphate and acetylcholinesterase

  7. Drug

    Sugammadex

    go.drugbank.com/drugs/DB06206
    ApprovedInvestigational

    Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015. … Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery.

  8. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). … Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).

  9. Drug

    Coral snake (micrurus fulvius) immune globulin antivenin (equine)

    go.drugbank.com/drugs/DB13883
    Approved

    North American Coral Snake Antivenin (Equine) is a horse-derived antivenin indicated for the treatment of envenomation caused by North American coral snake bites. … The antivenin is a refined, concentrated, and lyophilized preparation of serum globulins obtained by fractionating blood from healthy horses that have been immunized with eastern coral snake (Micrurus

  10. Drug

    Indocyanine green acid form

    go.drugbank.com/drugs/DB09374
    ApprovedInvestigational

    Indocyanine Green is a water soluble, tricarbocyanine dye with a peak spectral absorption at 800 nm. The chemical name for Indocyanine Green is 1 H-Benz[e]indolium, 2-[7-[1,3-dihydro-1,1-dimethyl-3-(4-sulfobutyl)-2H-benz[e] indol-2-ylide...